Proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in primary antiphospholipid syndrome. The multicenter ATHERO-APS study

The proprotein convertase subtilisin/kexin type 9 (PCSK9) is emerging as a novel cardiovascular risk factor. Levels of PCSK9 in thrombotic primary antiphospholipid syndrome (PAPS) have never been investigated. Cross sectional comparison of baseline characteristics of 91 PAPS patients enrolled in the...

Full description

Saved in:
Bibliographic Details
Published in:Journal of autoimmunity 2022-05, Vol.129, p.102832-102832, Article 102832
Main Authors: Bucci, Tommaso, Ames, Paul RJ, Cammisotto, Vittoria, Bartimoccia, Simona, Triggiani, Massimo, Parente, Roberta, Ciampa, Antonio, Pignatelli, Pasquale, Carnevale, Roberto, Pastori, Daniele
Format: Article
Language:English
Subjects:
Antiphospholipid syndrome
Antiphospholipid Syndrome - epidemiology
Cohort Studies
Cross-Sectional Studies
Female
Humans
Male
Middle Aged
PCSK9
Proprotein Convertase 9
Prospective Studies
Subtilisins
Thrombosis
Thrombosis - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The proprotein convertase subtilisin/kexin type 9 (PCSK9) is emerging as a novel cardiovascular risk factor. Levels of PCSK9 in thrombotic primary antiphospholipid syndrome (PAPS) have never been investigated. Cross sectional comparison of baseline characteristics of 91 PAPS patients enrolled in the multicenter prospective ATHERO-APS cohort study. PCSK9 levels were categorized into tertiles and the association with arterial and recurrent thrombosis were assessed by univariable and multivariable logistic regression analysis. Median age was 51 years and 71.4% (n = 65) were women. Overall, 33% (n = 30) experienced an arterial event while 31% (n = 28) had recurrent thrombotic events. Median PCSK9 levels were 1243 (1100–1650) pg/ml. Patients in the third PCSK9 tertile (>1458 pg/ml) showed a higher prevalence of dyslipidemia, lupus anticoagulant positivity and a history of previous arterial and recurrent thrombosis than patients in the first and second tertile. PCSK9 levels were higher in arterial than venous thrombosis (1502 vs. 1180 pg/ml, p = 0.002), and in patients with recurrent vs isolated thrombosis (1680 vs. 1150 pg/m, p 
ISSN:0896-8411
1095-9157
DOI:10.1016/j.jaut.2022.102832